Literature DB >> 22585662

Deletion of the ST2 proximal promoter disrupts fibroblast-specific expression but does not reduce the amount of soluble ST2 in circulation.

Brian P Lipsky1, Dean Y Toy, David A Swart, Molly D Smithgall, Dirke Smith.   

Abstract

IL-33 signals through ST2, which is expressed either as a full-length signaling receptor or a truncated soluble receptor that can suppress IL-33 activity. Previous data suggest that soluble ST2 mRNA in fibroblasts is coupled to a serum-inducible proximal promoter, while full-length ST2 expression in immune cells is directed from a distal promoter. In order to better understand the function of the alternative promoters and how they ultimately affect the regulation of IL-33, we generated a mouse in which the ST2 proximal promoter is deleted. Promoter deletion had no impact on ST2 expression in mast cells or their ability to respond to IL-33. In contrast, it resulted in a complete loss of both soluble and full-length ST2 mRNA in fibroblasts, which corresponded with both an inability to secrete soluble ST2 and a defect in IL-33 responsiveness. Importantly, in spite of the fibroblast defect, soluble ST2 concentrations were not reduced in the serum of naïve or allergen-exposed knockout mice. In summary, we found that ST2 promoter usage is largely cell-type dependent but does not dictate splicing. Moreover, the proximal promoter is not a major driver of circulating soluble ST2 under the conditions tested.
© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22585662     DOI: 10.1002/eji.201142274

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling.

Authors:  Jennifer E Ho; Wei-Yu Chen; Ming-Huei Chen; Martin G Larson; Elizabeth L McCabe; Susan Cheng; Anahita Ghorbani; Erin Coglianese; Valur Emilsson; Andrew D Johnson; Stefan Walter; Nora Franceschini; Christopher J O'Donnell; Abbas Dehghan; Chen Lu; Daniel Levy; Christopher Newton-Cheh; Honghuang Lin; Janine F Felix; Eric R Schreiter; Ramachandran S Vasan; James L Januzzi; Richard T Lee; Thomas J Wang
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

2.  Prospects to translate the biology of IL-33 and ST2 during organ transplantation into therapeutics to treat graft-versus-host disease.

Authors:  Ian C Scott; Kirsty F Houslay; E Suzanne Cohen
Journal:  Ann Transl Med       Date:  2016-12

Review 3.  Alarmins and Their Receptors as Modulators and Indicators of Alloimmune Responses.

Authors:  B M Matta; D K Reichenbach; B R Blazar; H R Turnquist
Journal:  Am J Transplant       Date:  2016-07-12       Impact factor: 8.086

4.  Elevated ST2 Distinguishes Incidences of Pediatric Heart and Small Bowel Transplant Rejection.

Authors:  L R Mathews; J M Lott; K Isse; A Lesniak; D Landsittel; A J Demetris; Y Sun; D F Mercer; S A Webber; A Zeevi; R T Fischer; B Feingold; H R Turnquist
Journal:  Am J Transplant       Date:  2015-12-11       Impact factor: 8.086

Review 5.  Various forms of tissue damage and danger signals following hematopoietic stem-cell transplantation.

Authors:  Abdulraouf Ramadan; Sophie Paczesny
Journal:  Front Immunol       Date:  2015-01-28       Impact factor: 7.561

Review 6.  Alternative Splicing in Cancer and Immune Cells.

Authors:  Antoine Bernard; Romain Boidot; Frédérique Végran
Journal:  Cancers (Basel)       Date:  2022-03-28       Impact factor: 6.639

7.  Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency.

Authors:  Praxedis Martin; Dominique Talabot-Ayer; Christian Alexander Seemayer; Solenne Vigne; Céline Lamacchia; Emiliana Rodriguez; Axel Finckh; Dirk E Smith; Cem Gabay; Gaby Palmer
Journal:  Arthritis Res Ther       Date:  2013-01-16       Impact factor: 5.156

8.  Myocardial fibrosis combined with NT-proBNP improves the accuracy of survival prediction in ADHF patients.

Authors:  Yiling Yao; Li Feng; Yanxiang Sun; Shifei Wang; Jie Sun; Bing Hu
Journal:  BMC Cardiovasc Disord       Date:  2021-05-28       Impact factor: 2.298

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.